Smartest Doc
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of Clinical Oncology, 08/08/2012
Bejar R et al. – Combining the Lower–Risk Prognostic Scoring System (LR–PSS) and EZH2 mutation status identifies 29% of patients with lower–risk myelodysplastic syndromes (MDS) with a worse–than–expected prognosis. These patients may benefit from earlier initiation of disease–modifying therapy.
